- Home
- CRTO vs ZLAB Comparison
CRTO vs ZLAB Comparison
Compare CRTO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRTO | ZLAB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | France | China |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.0B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CRTO | ZLAB |
|---|---|---|
| Price | $19.85 | $18.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $38.67 | ★ $57.22 |
| AVG Volume (30 Days) | 537.0K | ★ 989.7K |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | $441,629,000.00 |
| Revenue This Year | N/A | $30.20 |
| Revenue Next Year | $1.42 | $34.71 |
| P/E Ratio | $6.62 | ★ N/A |
| Revenue Growth | 0.53 | ★ 24.14 |
| 52 Week Low | $19.00 | $16.82 |
| 52 Week High | $47.27 | $44.34 |
Technical Indicators
Market Signals| Indicator | CRTO | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 33.31 |
| Support Level | $19.69 | $16.82 |
| Resistance Level | $21.39 | $18.67 |
| Average True Range (ATR) | 0.89 | 0.60 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 34.48 | 38.53 |
Price Performance
Historical ComparisonAbout CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.